Abstract:Metastasis is the spread of cancer cells from the primary tumour to distant sites and organs throughout the body. It is the primary cause of cancer morbidity and mortality, and is estimated to account for 90% of cancer-related deaths. During the initial steps of the metastatic cascade, epithelial cancer cells undergo an epithelial-mesenchymal transition (EMT), and as a result become migratory and invasive mesenchymal-like cells while acquiring cancer stem cell properties and therapy resistance. As EMT is involved in such a broad range of processes associated with malignant transformation, it has become an increasingly interesting target for the development of novel therapeutic strategies. Anti-EMT therapeutic strategies could potentially not only prevent the invasion and dissemination of cancer cells, and as such prevent the formation of metastatic lesions, but also attenuate cancer stemness and increase the effectiveness of more classical chemotherapeutics. In this review, we give an overview about the pros and cons of therapies targeting EMT and discuss some already existing candidate drug targets and high-throughput screening tools to identify novel anti-EMT compounds.

Targeting Epithelial–Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer

Epithelial-Mesenchymal Transition and Drug Resistance: Role, Molecular Mechanisms, and Therapeutic Strategies

Roles of epithelial-mesenchymal transition in cancer drug resistance.

Epithelial-to-Mesenchymal Transition: Liaison between Cancer Metastasis and Drug Resistance.

Epithelial–Mesenchymal Transition-Mediated Tumor Therapeutic Resistance

Cancer drug resistance induced by EMT: novel therapeutic strategies

Tackle Epithelial-Mesenchymal Transition With Epigenetic Drugs in Cancer

Epithelial-Mesenchymal Transition (EMT) as a Therapeutic Target

[Research Progress of the Role of EMT in EGFR-TKIs Resistance of Non-small Cell Lung Cancer].

Novel Therapeutic Strategies: Targeting Epithelial–mesenchymal Transition in Colorectal Cancer

Overcoming Therapeutic Resistance to Platinum-Based Drugs by Targeting Epithelial–Mesenchymal Transition

Research Progress of Epithelial-mesenchymal Transition Treatment and Drug Resistance in Colorectal Cancer

Research Progress on Relationship Between Epithelial-Mesenchymal Transitions and Drug Resistance in Breast Cancer

Epithelial–mesenchymal transition in colorectal cancer metastasis: A system review

Epithelial-mesenchymal transition as a therapeutic target for overcoming chemoresistance in pancreatic cancer

Emerging Role of F-box Proteins in the Regulation of Epithelial-Mesenchymal Transition and Stem Cells in Human Cancers

Exploring the Metabolic Vulnerabilities of Epithelial–Mesenchymal Transition in Breast Cancer

Epithelial–mesenchymal-transition-inducing transcription factors: new targets for tackling chemoresistance in cancer?

The role of epithelial–mesenchymal transition-regulating transcription factors in anti-cancer drug resistance

Epithelial–mesenchymal Transition Plays a Critical Role in Drug Resistance of Hepatocellular Carcinoma Cells to Oxaliplatin

New Insights into the Epithelial-to-Mesenchymal Transition in Cancer